Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.227
Index Copernicus (ICV 2018) – 157.72, MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print),   ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 8, August, p. 1095–1099

doi: 10.17219/acem/104558

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Comparing radioactive tracers 18F-FDG and 18F-FLT in the staging of diffuse large B-cell lymphoma by PET/CT examination: A single-center prospective study

Justyna Rybka1,B,C,D,E,F, Bogdan Małkowski2,A,B,C,D,E,F, Monika Olejniczak3,B,C, Ewa Chmielowska3,B,C, Ewelina Sokołowska4,C, Kazimierz Kuliczkowski1,B,E,F, Tomasz Wróbel1,A,B,C,D,E,F

1 Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Poland

2 Department of Positron Emission Tomography and Molecular Imagining, Collegium Medicum, Nicolaus Copernicus University, Toruń, Poland

3 Department of Oncology, Oncology Centre, Bydgoszcz, Poland

4 Department of Corporate Finance, University of Gdańsk, Poland

Abstract

Background. Positron emission tomography in combination with computer tomography (PET/CT) is a very important method of imaging patients with non-Hodgkin lymphomas (NHLs). It is used to define the initial grade of the disease and to assess early response to treatment and after chemotherapy. The most commonly used radioactive tracer is 18F-FDG, but 18F-FLT seems to be more specific.
Objectives. The aim of our study was to compare the staging of diffuse large B-cell lymphoma (DLBCL) with PET/CT examination using 18F-FLT and 18F-FDG.
Material and Methods. The study included 33 patients with newly diagnosed DLBCL (17 women and 16 men). The median age of the patients was 57 years. In each patient, 2 PET/CT examinations were performed before treatment, one using 18F-FLT and the second using 18F-FDG.
Results. The average maximum 18F-FDG uptake in the whole group of patients was higher than the average maximum of 18F-FLT. This was also true of individual patients; however, 3 patients with an aggressive disease course had greater FLT uptake than the other patients.
Conclusion. Our analysis suggests that PET/CT exams using 18F-FLT may be a useful diagnostic tool in patients with DLBCL.

Key words

diffuse large B-cell lymphoma, positron emission tomography, 18F-FLT

References (18)

  1. Kirby AM, Mikhaeel NG. The role of FDG-PET in the management of lymphoma: Practical guidelines. Nucl Med Commun. 2007;28(5):355–357.
  2. Been LB, Suurmeijer A, Cobben D, Jager PL, Hoekstra HJ, Elsinga PH. (18F) FLT-PET in oncology: Current status and opportunities. Eur J Nucl Med Mol Imaging. 2004;31(12):1659–1672.
  3. Moskowitz CH. Interim PET-CT in the management of diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2012;2012:397–401.
  4. Allen-Auerbach M, de Vos S, Czernin J. PET/computed tomography and lymphoma. Radiol Clin North Am. 2013;51(5):833–844.
  5. Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66(22):11055–11061.
  6. Barthel H, Cleij MC, Collingridge DR, et al. 3’-deoxy-3’-(18F) fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo positron emission tomography. Cancer Res. 2003;63(13):3791–3798.
  7. Wang R, Zhu H, Chen Y, et al. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT. Hematol Oncol. 2014;32(3):126–132.
  8. Omid S, Shields T, Shields AF. PET imaging of proliferation with pyrimidines. J Nucl Med. 2013;54(6):903–912.
  9. Tilly H, Dreyling M. Diffuse large B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2010;21:172–174.
  10. Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol. 1996;23(1):17–22.
  11. Bading JR. Kinetic analysis of 18F-FLT PET in lung tumors. J Nucl Med. 2012;53(3):506–507.
  12. Eckel F, Herrmann K, Schmidt S, et al. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine. J Nucl Med. 2009;50(9):1441–1447.
  13. Everitt SJ, Ball DL, Hicks RJ, et al. Differential 18F-FDG and 18F-FLT uptake on serial PET/CT imaging before and during definitive chemoradiation for non-small cell lung cancer. J Nucl Med. 2014;55(7):1069–1074.
  14. Woolf DK, Beresford M, Li SP, et al. Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer. Br J Cancer. 2014;110(12):2847–2854.
  15. Cho LP, Kim CK, Viswanathan AN. Pilot study 18F-fluorothymidine PET/CT in cervical and vaginal cancers before and after external beam radiation. Gyn Oncol Rep. 2015;14:34–37.
  16. Lee H, Kim S, Kim Y, et al. Early determination of prognosis by interim 39 deoxy-3918 F-fluorothymidine PET in patients with non-Hodgkin lymphoma. J Nucl Med. 2014;55(2):216–222.
  17. Wondergem MJ, Rizvi SNF, Jauw Y, et al. 18F-FDG or 3´-deoxy-3´-18F-fluorothymidine to detect transformation of follicular lymphoma. J Nucl Med. 2015;56(2):216–221.
  18. Herrmann K, Buck AK, Schuster T, et al. Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL. Oncotarget. 2014;5(12):4050–4059.